

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5203931

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ADIMAB LLC	10/16/2018
RECEIVING PARTY DATA	
Name:	COMPASS THERAPEUTICS LLC
Street Address:	245 FIRST STREET, THIRD FLOOR
City:	CAMBRIDGE
State/Country:	MASSACHUSETTS
Postal Code:	02142
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16123742
CORRESPONDENCE DATA	
Fax Number:	(617)217-4699
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6172174700
Email:	IPBoston.Docketing@nelsonmullins.com, jackeline.flores@nelsonmullins.com
Correspondent Name:	NELSON MULLINS RILEY & SCARBOROUGH LLP
Address Line 1:	ONE POST OFFICE SQUARE
Address Line 2:	FLOOR 30, SUITE 3000
Address Line 4:	BOSTON, MASSACHUSETTS 02109-2127
ATTORNEY DOCKET NUMBER:	CTN-006CN
NAME OF SUBMITTER:	AMY E. MANDRAGOURAS, ESQ.
SIGNATURE:	/Amy E. Mandragouras, Esq./
DATE SIGNED:	10/24/2018
Total Attachments: 4	
source=Adimab to Compass Executed Assignment_CTN-006#page1.tif	
source=Adimab to Compass Executed Assignment_CTN-006#page2.tif	
source=Adimab to Compass Executed Assignment_CTN-006#page3.tif	
source=Adimab to Compass Executed Assignment_CTN-006#page4.tif	

ASSIGNMENT

We, Adimab LLC, of Lebanon, New Hampshire, respectively, for good and valuable consideration paid to it by

Compass Therapeutics LLC

a Limited Liability Company of Delaware, having its principal place of business at 245 First Street, Third Floor, Cambridge, Massachusetts 02142, the receipt of which is hereby acknowledged, do hereby sell, assign and transfer unto said

Compass Therapeutics LLC

its successors and assigns, the entire interest for the United States of America and all foreign countries including all rights of priority under the International Convention for the Protection of Industrial Property in a certain invention or improvement in

AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF

described in an application

Executed by us of even date herewith and about to be filed

or

Application No. 16/032,639, filed on July 11, 2018; and International Application No. PCT/US2018/041612, filed on July 11, 2018

This application claims the benefit of the following provisional application(s):

Provisional Application No. 62/577259, filed on October 26, 2017
 Provisional Application No. 62/577257, filed on October 26, 2017
 Provisional Application No. 62/568231, filed on October 4, 2017
 Provisional Application No. 62/531259, filed on July 11, 2017
 Provisional Application No. 62/531190, filed on July 11, 2017

in the United States Patent and Trademark Office, and in all Letters Patent of the United States and all foreign countries which may or shall be granted on said invention, or any parts thereof, or on said application, or any divisional, continuing, reissue or other applications based in whole or in part thereon. And ASSIGNOR agrees, with said Limited Liability Company and its successors and assigns but at its expense and charges, hereafter to execute all applications, amended specifications, deed or other instrument, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and in all other countries to said Limited Liability Company, with specifications and claims in such form as shall be approved by the counsel of said Limited Liability Company and to vest and confirm in said Limited Liability Company, its successors and assigns, the legal title to all such patents.

PATENT

REEL: 047297 FRAME: 0232

CTN-006

And ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said Limited Liability Company, its successors and assigns.

And ASSIGNOR further hereby grants the attorneys/agents of Nelson Mullins Riley & Scarborough LLP, the power to insert on this Assignment the filing date and/or application number of said application.


ASSIGNOR:

ERIC KRAULAND

Signatory Name (print)

CHIEF SCIENTIFIC OFFICER


Signatory Title (print)



Signature, Adimab LLC

Date: October 16th 2018

Witness:


Signature

10/16/18
Date

ASSIGNEE:

I hereby acknowledge that rights in the above-identified application have transferred from the assignor(s) by virtue of their above execution of this Assignment and are hereby conveyed to Compass Therapeutics LLC, the Assignee, of which I am an authorized signatory.

JAMON BANKS

Signatory Name (print)

VP, LEGAL AFFAIRS

Signatory Title (print)

Signature, Compass Therapeutics LLC

Date:

10/23/18

Witness:

10/23/18

